Addition of apalutamide incurs no QOL cost

Adding apalutamide to standard androgen deprivation therapy (ADT) in patients with metastatic castration-sensitive prostate cancer does not adversely affect overall quality of life (QOL), including pain and fatigue.

The phase 3 TITAN study showed that the addition of apalutamide to ADT significantly improved overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. However, in these relatively well men it is important to assess whether this additional benefit comes at a cost of compromised quality of life.

The recently published Lancet Oncology (doi.org/10.1016/S1470-2045(19)30620-5) study used data from TITAN to look at the QOL impact of adding in additional androgen blockade.

Patient-reported outcomes were the Brief Pain Inventory-Short Form (BPI-SF), Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Prostate (FACT-P), and EuroQoL 5D questionnaire 5 level (EQ-5D-5L). The addition of apalutamide to standard ADT had no adverse impact on any of these parameters of overall QOL.

According to the authors, the results of the TITAN study showed substantial benefits for apalutamide plus ADT for overall survival and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer. It also demonstrated an overall health-related QOL was maintained, supporting the addition of apalutamide to ADT for a broad range of patients with metastatic castration-sensitive prostate cancer.

Web design and marketing agency Leamington Spa